Abstract:Drug design is usually understood as “an inventive process of finding new medications based on the knowledge of the biological target” – according to the Wikipedia definition – where “drug” is usually defined as a relatively small organic ligand binding to a biomolecule to either inhibit or promote its activity. [1] Methods of thus-defined drug design are well established in the early stages of drug discovery and focus mainly on identifying new chemical entities (NCEs) – molecules with desired biological activity. Along with activity, however, drugs must possess acceptable ADMET (Absorption, Distribution, Metabolism, Elimination, and Toxicity) properties. Although a few recent trends push ADMET optimization into drug design, these properties are still largely neglected until the lead optimization phase occurring later in drug discovery when the available chemical space is already narrowed by affinity and selectivity concerns. Usually one group of drug discovery researchers hands out lead molecules to a separate group of drug development scientists: “Our job is done, here are the active molecules. Now you worry about their other properties.” This separation could, and often does, lead to frustrating failures where all the lead compounds may, for example, turn out to be insoluble in water, impermeable via the intended route of administration, unacceptably metabolized by enzymes common to co-medications, or produce unacceptable adverse effects. All the effort and cost of discovering them would then be wasted. Authors of this article strongly believe in “ADMET design” – a paradigm where ADMET properties are included in the earliest stages of drug discovery and treated on equal footing with biological efficacy. This multidimensional search and optimization should be a normal function of the team of discovery chemists and other pharmaceutical scientists. The difficulty is that humans are not well-adapted to thinking in more than a few dimensions at once. In silico approaches are the solution as they facilitate integration of multiple variables and the most efficient use of experimental data. In the following sections we focus on machine learning approaches, such as Artificial Neural Networks (ANN) [2] or Support Vector Machines (SVM) [3], to QSAR/QSPR modeling [4] of ADMET properties. In QSAR/QSPR, chemical structures are encoded by calculated values of molecular descriptors serving as inputs to mathematical predictive models. ANN models, in particular, have been determined to be superior predictors over other methods. [5] Training several ANN or SVM and taking an arithmetic average of their outputs as the final answer usually enhances accuracy of prediction and is known as ANN Ensemble (ANNE) or SVM Ensemble (SVME) approaches. [6] Some researchers regard these techniques as “black boxes” meaning that although ANNE or SVME models can produce numerical outputs, their internal complexity precludes any descriptive interpretation of these results. Contrary to these stereotypical beliefs, predictive mathematical models of this type are quite interpretable and thus amenable to a direct use in drug design. We demonstrate this claim on specific examples.

Validating ADME QSAR Models Using Marketed Drugs

Quantitative Structure–activity Relationship: Promising Advances in Drug Discovery Platforms

In Silico Modeling on ADME Properties of Natural Products: Classification Models for Blood-Brain Barrier Permeability, Its Application to Traditional Chinese Medicine and in Vitro Experimental Validation

Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability

In Silicoadme/t Modelling for Rational Drug Design

Developing QSAR Models with Defined Applicability Domains on PPARγ Binding Affinity Using Large Data Sets and Machine Learning Algorithms.

Busting the Black Box Myth: Designing out Unwanted ADMET Properties with Machine Learning Approaches

Screening, Optimization, and ADMET Evaluation of HCJ007 for Pancreatic Cancer Treatment Through Active Learning and Dynamics Simulation

Predicting ADME properties in silico: methods and models

QSAR Modeling: Where Have You Been? Where Are You Going To?

The database makes the poison: How the selection of datasets in QSAR models impacts toxicant prediction of higher tier endpoints

Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery

Rethinking the applicability domain analysis in QSAR models

Statistical Evaluation of Cancer Drugs by QSPR Modeling

Recent Advances On In Silico Adme Modeling

Systematic Evaluation of Local and Global Machine Learning Models for the Prediction of ADME Properties

One size does not fit all: revising traditional paradigms for QSAR-based virtual screenings.

Review of MARCH-INSIDE & Complex Networks Prediction of Drugs: ADMET, Anti-Parasite Activity, Metabolizing Enzymes and Cardiotoxicity Proteome Biomarkers.

Large scale comparison of QSAR and conformal prediction methods and their applications in drug discovery

Centralized data sources and QSAR methods for the prediction of idiosyncratic adverse drug reaction

On the Virtues of Automated QSAR The New Kid on the Block